ALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Second Quarter Financial Results

Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million in the second quarter of 2025.
Gross margin was 72.7% compared to 74.2% in the second quarter of 2025. Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.
Net loss was $1.5 million, or $0.03 per share, compared to a Net income of $0.6 million, or $0.01 per share for the second quarter of 2025.
Adjusted net income was $7.3 million, or $0.12 per share, as compared to $5.7 million, or $0.12 per share for the second quarter of 2025.
Adjusted EBITDA was $8.4 million, compared to $9.3 million for the second quarter of 2025.
Cash and cash equivalents, restricted cash, and investments as of June 30, 2026 was $113.4 million, as compared to $103.6 million as of March 31, 2026, an increase of $9.8 million.

"We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities," said Michael Dale, President and CEO of Axogen, Inc. "Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026."

Summary of Business Highlights

Year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.

Publication of REPOSE, a prospective, randomized clinical study evaluating Axoguard Nerve Cap for symptomatic neuroma management, providing Level 1 evidence supporting nerve end protection and demonstrating favorable outcomes in pain burden, medication utilization, and recovery-related measures.

Initiated Nerve-RESTORE, a prospective, randomized, assessor-blinded study comparing Avance Nerve Graft to sural nerve autograft in mixed and motor nerve reconstruction, designed to generate Level 1 evidence supporting broader adoption of nerve repair globally.

Acquired a minority ownership stake in Trace Biosciences, including a limited right of first refusal, to support development of its nerve-specific imaging technology.

2026 Financial Guidance

For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s product portfolio includes Avance^® (acellular nerve allograft-arwx), Avance^® Nerve Graft, Axoguard Nerve Connector^®, Axoguard Nerve Protector^®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap^®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release and accompanying earnings call contain "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements under the heading "2026 Financial Guidance" and statements regarding our business model optimization plans; market development strategies and objectives; our strategic investments, including the expected benefits and opportunities of such investments; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our ability to sustain growth, operate profitably, generate positive cash flows, and fund our market development initiatives. These statements are based on management’s current expectations and estimates of trends and economic factors in the markets in which we are active. Words such as "expects," "anticipates," "objectives," "targets," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, "Risk Factors," in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net (Loss) Income and Net (Loss) Income Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.

These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Contact:

Axogen, Inc.

InvestorRelations@axogeninc.com


Axogen, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts)

	June 30, 2026			December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	94,572		$	35,548
Restricted cash		2,000			4,000
Investments		16,840			5,980
Accounts receivable, net of allowance for doubtful accounts of $734 and $948, respectively		34,126			26,169
Inventory		47,313			42,373
Prepaid expenses and other assets		5,525			6,352
Total current assets		200,376			120,422
Property and equipment, net		82,342			81,783
Operating lease right-of-use assets		13,845			12,732
Intangible assets, net		7,571			6,750
Other assets		729			—
Total assets	$	304,863		$	221,687

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$	28,399		$	21,184
Current maturities of long-term lease obligations		1,975			2,372
Total current liabilities		30,374			23,556

Long-term debt, net of debt discount and financing fees		—			48,387
Long-term lease obligations		18,091			16,870
Debt derivative liabilities		—			3,886
Other long-term liabilities		141			141
Total liabilities		48,606			92,840

Shareholders’ equity:
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 53,656,293 and 47,199,797 shares issued and outstanding, respectively		537			472
Additional paid-in capital		583,783			435,338
Accumulated deficit		(328,063	)		(306,963	)
Total shareholders’ equity		256,257			128,847
Total liabilities and shareholders’ equity	$	304,863		$	221,687


Axogen, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts)

	Three Months Ended						Six Months Ended
	June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Revenues	$	69,731		$	56,662		$	131,188		$	105,222
Cost of goods sold		19,057			14,644			34,325			28,271
Gross profit		50,674			42,018			96,863			76,951
Costs and expenses:
Sales and marketing		30,827			23,804			59,460			44,849
Research and development		8,589			6,853			16,106			12,944
General and administrative		13,414			9,689			26,285			19,147
Total costs and expenses		52,830			40,346			101,851			76,940
(Loss) income from operations		(2,156	)		1,672			(4,988	)		11
Other income (expense):
Investment income		786			225			1,554			497
Interest expense		(1	)		(1,977	)		(695	)		(4,227	)
Loss on extinguishment of debt		—			—			(16,849	)		—
Change in fair value of debt derivative liabilities		—			480			—			322
Other (expense) income, net		(145	)		179			(122	)		142
Total other income (expense), net		640			(1,093	)		(16,112	)		(3,266	)
Net (loss) income	$	(1,516	)	$	579		$	(21,100	)	$	(3,255	)

Weighted average common shares outstanding — basic		53,339,258			46,063,092			52,562,976			45,605,419
Weighted average common shares outstanding — diluted		53,339,258			47,980,830			52,562,976			45,605,419

Net (loss) income per common share — basic	$	(0.03	)	$	0.01		$	(0.40	)	$	(0.07	)
Net (loss) income per common share — diluted	$	(0.03	)	$	0.01		$	(0.40	)	$	(0.07	)


Axogen, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands)

	Six Months Ended
	June 30, 2026			June 30, 2025
Cash flows from operating activities:
Net loss	$	(21,100	)	$	(3,255	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation		3,211			3,385
Amortization of right-of-use assets		854			184
Amortization of intangible assets		212			133
Amortization of debt discount and deferred financing fees		68			442
(Recovery of) provision for bad debts		(52	)		386
Loss on disposal of equipment		7			—
Change in fair value of debt derivative liabilities		—			(322	)
Investment gains, net		(110	)		(121	)
Loss on extinguishment of debt		16,849			—
Stock-based compensation expense		15,609			8,077
Change in operating assets and liabilities:
Accounts receivable		(7,905	)		(4,310	)
Inventory		(4,940	)		(3,591	)
Prepaid expenses and other assets		827			(81	)
Other assets		(729	)		—
Accounts payable and accrued expenses		7,118			(5,755	)
Operating lease obligations		(1,130	)		(542	)
Cash paid for interest portion of financing lease obligations		(3	)		(2	)
Other long-term liabilities		—			(77	)
Net cash provided by (used in) operating activities		8,786			(5,449	)

Cash flows from investing activities:
Purchase of property and equipment		(3,682	)		(978	)
Purchase of investments		(18,750	)		(7,837	)
Proceeds from sale of investments		8,000			4,000
Cash payments for intangible assets		(1,032	)		(793	)
Net cash used in investing activities		(15,464	)		(5,608	)

Cash flows from financing activities:
Proceeds from issuance of common stock		134,044			—
Payment of stock issuance costs		(792	)		—
Repayment of long-term debt		(48,585	)		—
Fees paid to lender related to debt extinguishment		(20,498	)		—
Fees paid to third parties related to debt extinguishment		(107	)		—
Payments of employee tax withholding on vested stock awards		(9,273	)		—
Cash paid for debt portion of financing lease obligations		(9	)		(8	)
Proceeds from exercise of stock options and ESPP stock purchases		8,922			3,547
Net cash provided by financing activities		63,702			3,539
Net increase (decrease) in cash and cash equivalents, and restricted cash		57,024			(7,518	)
Cash and cash equivalents, and restricted cash, beginning of period		39,548			33,554
Cash and cash equivalents, and restricted cash, end of period	$	96,572		$	26,036


Axogen, Inc. Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited) (in thousands, except share amounts)

	Common Stock			Additional Paid-in Capital			Accumulated Deficit			Total Shareholders' Equity
	Shares	Amount		Additional Paid-in Capital			Accumulated Deficit			Total Shareholders' Equity
Three Months Ended June 30, 2026
Balance at March 31, 2026	53,153,471	$	532	$	570,823		$	(326,547	)	$	244,808
Net loss	—		—		—			(1,516	)		(1,516	)
Stock-based compensation	—		—		8,766			—			8,766
Issuance of restricted and performance stock units, net of shares withheld for withholding taxes	134,892		1		(498	)		—			(497	)
Exercise of stock options and employee stock purchases under the ESPP	367,930		4		4,692			—			4,696
Balance at June 30, 2026	53,656,293	$	537	$	583,783		$	(328,063	)	$	256,257

Six Months Ended June 30, 2026
Balance at December 31, 2025	47,199,797	$	472	$	435,338		$	(306,963	)	$	128,847
Net loss	—		—		—			(21,100	)		(21,100	)
Issuance of common shares	4,600,000		46		133,206			—			133,252
Stock-based compensation	—		—		15,609			—			15,609
Issuance of restricted and performance stock units, net of shares withheld for withholding taxes	1,120,688		11		(9,284	)		—			(9,273	)
Exercise of stock options and employee stock purchases under the ESPP	735,808		8		8,914			—			8,922
Balance at June 30, 2026	53,656,293	$	537	$	583,783		$	(328,063	)	$	256,257

Three Months Ended June 30, 2025
Balance at December 31, 2024	45,512,623	$	455	$	400,004		$	(295,094	)	$	105,365
Net income	—		—		—			579			579
Stock-based compensation	—		—		5,168			—			5,168
Issuance of restricted and performance stock units	113,923		1		(1	)		—			—
Exercise of stock options and employee stock purchases under the ESPP	138,744		1		1,163			—			1,164
Balance at June 30, 2025	45,765,290	$	457	$	406,334		$	(294,515	)	$	112,276

Six Months Ended June 30, 2025
Balance at December 31, 2024	44,148,836	$	441	$	394,726		$	(291,260	)	$	103,907
Net loss	—		—		—			(3,255	)		(3,255	)
Stock-based compensation	—		—		8,077			—			8,077
Issuance of restricted and performance stock units	1,219,137		12		(12	)		—			—
Exercise of stock options and employee stock purchases under the ESPP	397,317		4		3,543			—			3,547
Balance at June 30, 2025	45,765,290	$	457	$	406,334		$	(294,515	)	$	112,276


Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)

*EBITDA & Adjusted EBITDA*	Three Months Ended						Six Months Ended
	June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Net (loss) income	$	(1,516	)	$	579		$	(21,100	)	$	(3,255	)
Depreciation and amortization expense		1,717			1,723			3,422			3,518
Investment income		(786	)		(225	)		(1,554	)		(497	)
Income tax expense		221			37			188			66
Interest expense		1			1,977			695			4,227
EBITDA - non-GAAP	$	(363	)	$	4,091		$	(18,349	)	$	4,059
EBITDA margin - non-GAAP	(0.5) %				7.2	%	(14.0) %				3.9	%

Non-cash stock-based compensation expense		8,766			5,168			15,609			8,077
Loss on extinguishment of debt		—			—			16,849			—
Adjusted EBITDA - non-GAAP	$	8,403		$	9,259		$	14,109		$	12,136
Adjusted EBITDA margin - non-GAAP		12.1	%		16.3	%		10.8	%		11.5	%

*Adjusted Net Income*	Three Months Ended June 30, 2026
	GAAP Results			Non-cash Stock-based Compensation Expense			Dilutive Shares Impact⁽¹⁾			Adjusted Results
	GAAP Results			Non-cash Stock-based Compensation Expense			Dilutive Shares Impact⁽¹⁾			Adjusted Results
Revenues	$	69,731		$	—					$	69,731
Cost of goods sold		19,057			(1,209	)					17,848
Gross profit		50,674			1,209						51,883
Costs and expenses:
Sales and marketing		30,827			(2,004	)					28,823
Research and development		8,589			(1,795	)					6,794
General and administrative		13,414			(3,758	)					9,656
Total costs and expenses		52,830			(7,557	)					45,273
(Loss) income from operations		(2,156	)		8,766						6,610
Other income (expense):
Investment income		786			—						786
Interest expense		(1	)		—						(1	)
Other expense, net		(145	)		—						(145	)
Total other income, net		640			—						640
Net (loss) income	$	(1,516	)	$	8,766					$	7,250

Weighted average common shares outstanding - diluted		53,339,258			53,339,258			6,234,467			59,573,725
Net (loss) income per common share - diluted	$	(0.03	)	$	0.16		$	(0.01	)	$	0.12

__________

(1) Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.


Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)

*Adjusted Net Income*	Three Months Ended June 30, 2025
	GAAP Results			Non-cash Stock-based Compensation Expense			Adjusted Results
	GAAP Results			Non-cash Stock-based Compensation Expense			Adjusted Results
Revenues	$	56,662		$	—		$	56,662
Cost of goods sold		14,644			(710	)		13,934
Gross profit		42,018			710			42,728
Costs and expenses:
Sales and marketing		23,804			(1,314	)		22,490
Research and development		6,853			(1,029	)		5,824
General and administrative		9,689			(2,115	)		7,574
Total costs and expenses		40,346			(4,458	)		35,888
Income from operations		1,672			5,168			6,840
Other income (expense):
Investment income		225			—			225
Interest expense		(1,977	)		—			(1,977	)
Change in fair value of debt derivative liabilities		480			—			480
Other income, net		179			—			179
Total other expense, net		(1,093	)		—			(1,093	)
Net income	$	579		$	5,168		$	5,747

Weighted average common shares outstanding - diluted		47,980,830			47,980,830			47,980,830
Net income per common share - diluted	$	0.01		$	0.11		$	0.12


Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)

*Adjusted Net Income*	Six Months Ended June 30, 2026
	GAAP Results			Non-cash Stock-based Compensation Expense			Loss on Extinguishment of Debt		Dilutive Shares Impact⁽¹⁾			Adjusted Results
	GAAP Results			Non-cash Stock-based Compensation Expense			Loss on Extinguishment of Debt		Dilutive Shares Impact⁽¹⁾			Adjusted Results
Revenues	$	131,188		$	—		$	—				$	131,188
Cost of goods sold		34,325			(2,129	)		—					32,196
Gross profit		96,863			2,129			—					98,992
Costs and expenses:
Sales and marketing		59,460			(3,561	)		—					55,899
Research and development		16,106			(3,214	)		—					12,892
General and administrative		26,285			(6,705	)		—					19,580
Total costs and expenses		101,851			(13,480	)		—					88,371
(Loss) income from operations		(4,988	)		15,609			—					10,621
Other income (expense):
Investment income		1,554			—			—					1,554
Interest expense		(695	)		—			—					(695	)
Loss on extinguishment of debt		(16,849	)		—			16,849					—
Other expense, net		(122	)		—			—					(122	)
Total other (expense) income, net		(16,112	)		—			16,849					737
Net (loss) income	$	(21,100	)	$	15,609		$	16,849				$	11,358

Weighted average common shares outstanding - diluted		52,562,976			52,562,976			52,562,976		5,966,877			58,529,853
Net (loss) income per common share - diluted	$	(0.40	)	$	0.30		$	0.32	$	(0.02	)	$	0.19


Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)

*Adjusted Net Income*	Six Months Ended June 30, 2025
	GAAP Results			Non-cash Stock-based Compensation Expense			Dilutive Shares Impact⁽¹⁾			Adjusted Results
	GAAP Results			Non-cash Stock-based Compensation Expense			Dilutive Shares Impact⁽¹⁾			Adjusted Results
Revenues	$	105,222		$	—					$	105,222
Cost of goods sold		28,271			(700	)					27,571
Gross profit		76,951			700						77,651
Costs and expenses:
Sales and marketing		44,849			(1,898	)					42,951
Research and development		12,944			(1,749	)					11,195
General and administrative		19,147			(3,730	)					15,417
Total costs and expenses		76,940			(7,377	)					69,563
Income from operations		11			8,077						8,088
Other income (expense):
Investment income		497			—						497
Interest expense		(4,227	)		—						(4,227	)
Change in fair value of debt derivative liabilities		322			—						322
Other income, net		142			—						142
Total other expense, net		(3,266	)		—						(3,266	)
Net (loss) income	$	(3,255	)	$	8,077					$	4,822

Weighted average common shares outstanding - diluted		45,605,419			45,605,419			2,650,576			48,255,995
Net (loss) income per common share - diluted	$	(0.07	)	$	0.18		$	(0.01	)	$	0.10


*Free Cash Flow*	Six Months Ended June 30,
		2026			2025
Net cash provided by (used in) operating activities	$	8,786		$	(5,449	)
Purchase of property and equipment		(3,682	)		(978	)
Cash payments for intangible assets		(1,032	)		(793	)
Free cash flow	$	4,072		$	(7,220	)